Skip to main content
Premium Trial:

Request an Annual Quote

Swelling R&D Doubles Deltagen s Net Loss in Q4 Despite Strong Sales

NEW YORK, Feb. 13 - Deltagen on Tuesday posted strong growth in revenue in the fourth quarter although a surge in R&D spending doubled its net loss year over year.


For the period ended Dec. 31, Deltagen said that strong sales of its DeltaBase gene function database helped generate $2.5 million in total revenue compared with $1.3 million one year ago.


R&D spending in the quarter, which clocked in at $13.3 million compared with $6.8 million in the year-ago period, helped swell overall expenses to nearly $18 million compared with almost $11 million last year.


As a result, Deltagen posted a net loss of $15 million, or $.48 per share, in the current quarter compared with $7.5 million, or $.26 per share, last year.


The Redwood City, Calif.-based company said it had $76.5 million in the bank as of Dec. 31.


On Monday, Deltagen said it intends to acquire Bristol-Myers Squibb's Pharma Research Labs division for approximately $23.5 million in stock. The deal, which would give Deltagen the keys to a fully functioning small molecule-drug discovery firm, "will significantly advance Deltagen's efforts in using its validated targets for identifying lead candidate compounds for drug development," the company had said.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.